February 14, 2022
Researchers at the University and the University Hospital of Bonn have developed a method that could be used to diagnose atherosclerosis. Using self-learning software, they were able to identify vascular changes in patients with peripheral arterial disease (PAD), often at an early stage. Although these early stages do not yet cause symptoms, they are nevertheless already associated with increased mortality. The algorithm used photos from an organ not normally associated with PAD: the eye. The results have now been published in the journal Scientific Reports.
February 14, 2022
TheWaytoMyHeart.org, a national non-profit Peripheral Artery Disease (PAD) patient advocacy group out of California, announced today that February 19, 2022 will be the first annual national “Red Sock Day” building awareness for Peripheral Artery Disease (PAD), its patients and treatment. The official proclamation will take place Wednesday February 16 at 10 am CST.
PAD is a disease that affects over 12 million Americans. Left untreated, PAD can lead to resting leg pain, foot wounds that won’t heal, gangrene and even amputation. Yet the majority of cases go undiagnosed, in part du...
January 17, 2022
At this year’s International Symposium on Endovascular Therapy (ISET 2022; 16–19 January, Hollywood, USA), experts presented an array of late-breaking trial results on topics ranging from venous stenting to abdominal aortic aneurysm (AAA) sac sealing. Waseem Wahood (Dr Kiran C Patel College of Allopathic Medicine, Davie, USA) gave a US national perspective on disparities in the treatment of peripheral arterial disease (PAD) and chronic limb-threatening ischaemia (CLTI).
December 8, 2021
There is an increased risk for venous thromboembolism (VTE) and peripheral vascular disease (PVD) among patients with psoriatic disease, according to a review published online Dec. 1 in JAMA Dermatology.
November 16, 2021
Peripheral arterial disease (PAD) patients face a high risk of limb amputation, according to the European Journal of Vascular and Endovascular Surgery.
The ultimate aim of this study was to assess the link between long term risk of hospitalization for heart failure (HHF) and lower extremity minor and major amputation (LEA) in patients initiating sodium glucose cotransporter 2 inhibitors (SGLT2i) suffering from type 2 diabetes and PAD.
Three-year outcome of directional atherectomy and drug coated balloon for the treatment of common femoral artery steno-occlusive lesions
November 14, 2021
CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS
Background: Endarterectomy is considered the gold standard therapy for common femoral artery (CFA) steno-occlusive lesions, but a significant risk of perioperative mortality and complications has been reported.
Objective: Aim of this study is to evaluate the efficacy at a long-term follow-up of patients with CFA steno-occlusive lesions treated with directional atherectomy and drug coated balloon (DCB).
November 8, 2021
Royal Philips today announced the results of a new large-scale real-world analysis of Centers for Medicare & Medicaid Services (CMS) data on the health outcomes of peripheral vascular interventions guided by intravascular ultrasound (IVUS).
November 8, 2021
Summary: Patients with peripheral arterial disease (PAD) are at very high risk of cardiovascular events, but risk factor management is usually suboptimal. This Joint Task Force from the European Atherosclerosis Society and the European Society of Vascular Medicine has updated evidence on the management on dyslipidaemia and thrombotic factors in patients with PAD. Guidelines recommend a low-density lipoprotein cholesterol (LDLC) goal of more than 50% reduction from baseline and <1.4 mmol/L (<55 mg/dL) in PAD patients. As demonstrated by randomized controlled trials, lowering LDL-C not only...
November 2, 2021
JOURNAL OF THE AMERICAN HEART ASSOCIATION
Background: Ankle‐brachial index (ABI) is used to identify lower‐extremity peripheral artery disease (PAD). However, its association with severe ischemic leg outcomes (eg, amputation) has not been investigated in the general population.
October 28, 2021
Patients with peripheral artery disease (PAD) undergoing lower extremity revascularization (LER) benefit from low-dose rivaroxaban and aspirin therapy, suggests a study published in the Circulation. Patients with peripheral artery disease (PAD) are at heightened risk of acute limb ischemia (ALI), a thrombotic event associated with amputation, disability, and mortality. Prior lower extremity revascularization (LER) is associated with increased ALI risk in chronic peripheral artery disease (PAD).